Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 20Other hematologic neoplasm 14Head & Neck 3Thoracic 2Myeloid 2Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1Gastrointestinal 1Classical hematology 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Indium × Plasma cell × Clear all
NCT05363111 2025-10-29

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡